BioTelemetry (BEAT) Tops Q4 EPS by 4c

BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.04, $0.04 better than the analyst estimate of $0.00. Revenue for the quarter came in at $37.2 million versus the consensus estimate of $38.4 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral